Uniqure B.V. buy melinda
Start price
27.06.17
/
50%
€5.41
Target price
18.07.17
€6.13
Performance (%)
7.52%
End price
18.07.17
€5.82
Summary
This prediction ended on 18.07.17 with a price of €5.82. With a performance of 7.52%, the BUY prediction by melinda for Uniqure B.V. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Uniqure B.V. | -2.859% | -2.859% | 49.261% | -9.883% |
| iShares Core DAX® | 0.721% | 4.566% | 24.333% | 64.224% |
| iShares Nasdaq 100 | -0.413% | 1.884% | 8.848% | 107.611% |
| iShares Nikkei 225® | 3.500% | 7.196% | 24.030% | 57.276% |
| iShares S&P 500 | 0.489% | 2.436% | 6.048% | 67.009% |
According to melinda what are the pros and cons of Uniqure B.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Uniqure B.V. diskutieren
Gesundheit | Biotechnologie | Niederlande
Aktualisiert Phase 1/2 nach dem Kongress der Internationalen Gesellschaft für Thrombose und Hämostase (ISTH) 2017, die 11. Juli 2017. Phase - 2b - Studie zu Q3 2017 beginnen.
Stopped prediction by melinda for Uniqure B.V.
Uniqure B.V.
Start price
Target price
Perf. (%)
€19.00
27.12.21
27.12.21
-
27.12.22
27.12.22
8.55%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€32.45
29.08.20
29.08.20
€40.00
04.11.21
04.11.21
-7.18%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€38.10
30.08.18
30.08.18
€40.59
25.02.19
25.02.19
31.53%
25.02.19
25.02.19
Could be worthwhile Investment >10% per year